IRIDEX CORP - 10-K Filing Summary
Business Context and Reporting Period
Company: IRIDEX Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: January 3, 2004 (53-week fiscal year)
Business Overview: IRIDEX is a worldwide provider of semiconductor-based laser systems for ophthalmology (treating eye diseases like AMD, diabetic retinopathy, and glaucoma) and dermatology (treating skin conditions and hair removal). Products are sold domestically via a direct sales force and internationally through 66 independent distributors in 107 countries.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2003 | Fiscal 2002 | Fiscal 2001 |
|---|---|---|---|
| Total Sales | $31,699 | $30,634 | $27,275 |
| Gross Profit | $14,071 | $13,588 | $13,070 |
| Gross Margin | 44.4% | 44.4% | 47.9% |
| Operating Loss | $(48) | $(181) | $(1,989) |
| Net Income | $371 | $150 | $(1,273) |
| Cash & Equivalents | $10,541 | $9,186 | $4,613 |
| Available-for-Sale Securities | $5,751 | $2,356 | $4,489 |
| Total Liquidity | $16,292 | $11,542 | $9,102 |
| Debt | $0 | $0 | $0 |
Note: Net Income includes a tax benefit. Operating loss was minimal in 2003 due to interest income offsetting operating expenses.
Material Changes vs. Prior Period
- Revenue Growth: Total sales increased 3.5% to $31.7 million in 2003 compared to 2002. This was driven by an 8.2% increase in ophthalmology sales ($26.2 million) which offset a 14.3% decline in dermatology sales ($5.5 million).
- Segment Performance:
- Ophthalmology: Domestic sales rose 9.8% due to increased unit sales of delivery devices and service revenue. International sales rose 6.0%.
- Dermatology: Domestic sales fell 17.0% primarily due to decreased unit sales of the DioLite laser and lower average selling prices. International dermatology sales remained flat.
- Profitability: The company returned to net profitability ($371k) after a net loss in 2001, though it remained near breakeven on an operating basis. Gross margin remained stable at 44.4%.
- Expenses: Research and Development (R&D) expenses decreased 6.6% to $4.0 million. Selling, General, and Administrative (SG&A) expenses increased 6.7% to $10.1 million.
Guidance, Outlook, and Risks
- Outlook: Management expects to continue facing challenges in a difficult economic environment. Future growth is anticipated from new product introductions, peripheral delivery devices, and service revenue. The company plans to increase R&D expenditures in 2004.
- Key Risks:
- Reimbursement: Sales of ophthalmic products are heavily dependent on third-party reimbursement policies (e.g., CMS/Medicare). Uncertainty regarding coverage for procedures like Transpupillary Thermotherapy (TTT) for AMD impacts sales.
- Competition: Intense competition from companies like Lumenis, Carl Zeiss, and Alcon, as well as pharmaceutical alternatives.
- Supply Chain: Reliance on sole-source suppliers for critical components (optics, laser diodes) creates manufacturing risks.
- International Exposure: Approximately 36.7% of sales are international, exposing the company to currency fluctuations and foreign regulatory changes.
- Clinical Trials: Success depends on the outcome of clinical trials, specifically the TTT4CNV trial for wet AMD, which completed enrollment in March 2003.
Investor Verification Checklist
- Reimbursement Status: Verify current Medicare/Medicaid coverage policies for TTT procedures in key states, as this directly impacts OcuLight SLx sales.
- Inventory Levels: Review the reduction in inventory ($2.0 million decrease in 2003) to ensure it aligns with demand forecasts and does not indicate obsolescence.
- Supplier Concentration: Assess the stability of sole-source suppliers for critical laser components.
- Cash Burn vs. Liquidity: Confirm that the $16.3 million in liquidity is sufficient to fund operations and R&D without dilution, given the company's history of near-breakeven operating results.
- Stock Option Dilution: Review the 2.0 million shares available for future issuance under equity compensation plans and the weighted average exercise price ($4.91) relative to current market price.